We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-7.53%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$319M
AUM Growth
-$42M
Cap. Flow
-$13.7M
Cap. Flow %
-4.3%
Top 10 Hldgs %
40.4%
Holding
86
New
14
Increased
23
Reduced
18
Closed
23

Top Buys

1
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
2
BHVN icon
Biohaven
BHVN
+$8.11M
3
CGON icon
CG Oncology
CGON
+$6.41M
4
KRRO icon
Korro Bio
KRRO
+$5.53M
5
SYRE icon
Spyre Therapeutics
SYRE
+$5.07M

Top Sells

1
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
2
JBIO
Jade Biosciences
JBIO
+$6.65M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.92M
4
TGTX icon
TG Therapeutics
TGTX
+$5.19M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.44M

Sector Composition

1 Healthcare 89.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$4.31B
$5.04M 1.58%
95,000
+21,998
+30% +$1.44M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.31B
$4.82M 1.51%
117,388
-7,612
-6% -$304K
INSM icon
28
Insmed
INSM
$23.5B
$4.36M 1.36%
65,000
-85,000
-57% -$3.3M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$4.31M 1.35%
40,000
-32,761
-45% -$3.28M
SVRA icon
30
Savara
SVRA
$1.13B
$4.24M 1.33%
1,050,876
-549,124
-34% -$2.44M
TNYA icon
31
Tenaya Therapeutics
TNYA
$177M
$4.18M 1.31%
1,350,000
+575,000
+74% +$2.37M
REPL icon
32
Replimune Group
REPL
$859M
$4.05M 1.27%
450,000
-200,000
-31% -$1.39M
ENGN icon
33
enGene Therapeutics
ENGN
$122M
$3.96M 1.24%
420,331
+220,331
+110% +$2.83M
ACAD icon
34
Acadia Pharmaceuticals
ACAD
$4.38B
$3.66M 1.14%
225,000
– –
BBIO icon
35
BridgeBio Pharma
BBIO
$15.9B
$3.55M 1.11%
140,000
-35,000
-20% -$957K
KRRO icon
36
Korro Bio
KRRO
$177M
$3.39M 1.06%
+100,000
New +$5.53M
NUVB icon
37
Nuvation Bio
NUVB
$2.02B
$3.36M 1.05%
+1,150,000
New +$3.51M
BBOT
38
BridgeBio Oncology
BBOT
$686M
$3.07M 0.96%
300,000
– –
TSHA icon
39
Taysha Gene Therapies
TSHA
$1.71B
$2.8M 0.88%
1,250,000
+300,000
+32% +$873K
CABA icon
40
Cabaletta Bio
CABA
$461M
$2.77M 0.87%
370,899
-4,101
-1% -$50.3K
NGNE icon
41
Neurogene
NGNE
$744M
$2.55M 0.8%
70,000
+45,000
+180% +$1.59M
JANX icon
42
Janux Therapeutics
JANX
$992M
$2.09M 0.66%
+50,000
New +$2.35M
ARVN icon
43
Arvinas
ARVN
$517M
$2M 0.63%
75,000
+35,000
+88% +$1.12M
RGNX icon
44
Regenxbio
RGNX
$511M
$1.99M 0.62%
170,000
+50,000
+42% +$778K
CYTK icon
45
Cytokinetics
CYTK
$10.9B
$1.8M 0.56%
33,200
+13,200
+66% +$797K
ELEV
46
DELISTED
Elevation Oncology
ELEV
$1.62M 0.51%
600,000
+350,000
+140% +$1.32M
KRYS icon
47
Krystal Biotech
KRYS
$10.5B
$1.56M 0.49%
8,500
-5,500
-39% -$923K
ANNX icon
48
Annexon
ANNX
$950M
$1.52M 0.48%
+310,000
New +$1.6M
PRQR icon
49
ProQR Therapeutics
PRQR
$240M
$1.49M 0.47%
+900,000
New +$1.75M
ATYR
50
aTyr Pharma
ATYR
$50M
$1.25M 0.39%
800,000
+200,000
+33% +$348K
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ghost Tree Capital held 86 positions worth $319M, down 12% from $361M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital withdrew a net $13.7M in Q2 2024, closing 23 positions and reducing 18 holdings. Its most notable exit was Jade Biosciences, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Ascendis Pharma A/S worth $11.8M.

  • Ghost Tree Capital's largest Q2 2024 buy was Ascendis Pharma A/S: 86,721 shares worth $11.8M.
  • Ghost Tree Capital added most to Biohaven in Q2 2024, an estimated $8.11M increase.
  • Ghost Tree Capital's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $8.99M.
  • Ghost Tree Capital fully exited Jade Biosciences in Q2 2024, selling an estimated $6.65M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $319M portfolio in Q2 2024.
  • Ghost Tree Capital opened 14 new positions and closed 23 in Q2 2024.
  • Ghost Tree Capital's portfolio value fell 12% quarter-over-quarter to $319M.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.